Growing Demand For Tamper-Resistant Pseudoephedrine (PSE) Products
The global respiratory drugs market, a part of the healthcare industry, grew at a compound annual growth rate (CAGR) of around 6% during the historic period. The healthcare industry showed a steady growth. The growth is mainly due to the increase in demand for drugs for respiratory diseases as a result of rise air pollution levels around the world. According to WHO, 98% of cities in low and middle income countries do not meet air quality standards.
In the forecast period, the global respiratory drugs market size is expected to be over $70 billion by 2021, growing at a CAGR of nearly 7%.
This is expected due to the rise in global air pollution levels will lead to higher number of respiratory diseases thus driving the respiratory drugs market. Furthermore, rising population, increase in dispensable income, and increasing per capita incomes are expected to drive the global respiratory drugs market in the future.
Find TBRC’s report on the respiratory drugs market: https://www.thebusinessresearchcompany.com/report/respiratory-diseases-drugs-global-market-report-2018
The demand for PSE-containing cold, allergy, and sinus products is growing due to their effectiveness and convenience. PSE is an active ingredient found in various cold, allergy, and sinus drugs that can provide congestion relief. However, PSE-containing medicines are mostly sold as a prescription drug, as PSE can also be used for the illegal manufacture of methamphetamine, a recreational drug.
Major companies in the respiratory drugs market, offering PSE technology include GlaxosmithKline Plc., AstraZeneca Plc. And Merck & Co.
Download a sample report: https://www.thebusinessresearchcompany.com/sample.aspx?id=282&type=smp
Respiratory Diseases Drugs Global Market TrendThe demand for PSE-containing cold, allergy, and sinus products is growing due to their effectiveness and convenience. PSE is an active ingredient found in various cold, allergy, and sinus drugs that can provide congestion relief. However, PSE-containing medicines are mostly sold as a prescription drug, as PSE can also be used for the illegal manufacture of methamphetamine, a recreational drug. This has led drug manufacturers to produce tamper-resistant PSE products. For instance, in March 2017, pharmaceutical companies Acura Pharmaceuticals Inc. and MainPointe Pharmaceuticals LLC entered into an agreement, enabling MainPointe Pharmaceuticals LLC to market NEXAFED and NEXAFED Sinus products in the US and Canada. These drugs utilize tamper-resistant PSE formulation to prevent the illicit production of methamphetamine.
The companies covered are GlaxosmithKline Plc, AstraZeneca Plc, Merck & Co, Novartis AG, and Johnson & Johnson.
The countries covered are USA, China, Germany, Brazil, Japan, UK, Spain, Russia, France, Australia, Italy, India and rest of the world.
Respiratory Diseases Drugs Global Market SegmentationThe respiratory diseases drugs market is segmented into Anti-Asthmatics And COPD Drugs; and Cough And Cold Preparations.
Anti-Asthmatics And COPD Drug companies produce drugs that can be used to relieve the frequency of acute attacks of asthma, emphysema, chronic bronchitis, and nocturnal awakenings.
Cough And Cold Preparations Drug companies produce drugs containing active ingredients such as acetaminophen, antihistamines, dextromethorphan, decongestants, and ethanol that can be used to treat cough and cold.
About The Business Research Company.
The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.
Contact Information.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on Linkedin: https://in.linkedin.com/company/the-business-research-company